Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

INTRODUCTION: In transplant-eligible, newly diagnosed multiple myeloma (NDMM) patients, autologous peripheral blood stem cell (PBSC) collection is usually pursued after induction therapy. While induction regimens are constantly refined regarding response, their impact on PBSC collection is not fully...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauer, Sandra, Kriegsmann, Katharina, Nientiedt, Cathleen, Schmitt, Anita, Müller-Tidow, Carsten, Raab, Marc-Steffen, Kauer, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626396/
https://www.ncbi.nlm.nih.gov/pubmed/37936633
http://dx.doi.org/10.1159/000529691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626396/
https://www.ncbi.nlm.nih.gov/pubmed/37936633
http://dx.doi.org/10.1159/000529691

Ejemplares similares